Some gene therapy manufacturers, like bluebird bio, Vertex Pharmaceuticals Incorporated and Sarepta Therapeutics, Inc., are beginning to see a ramp up in their commercial businesses and reported an expanding pipeline of patients beginning the process to start treatment in the second quarter. But the number of patients treated with new gene therapies remains limited and companies focused on hemophilia, including CSL Limited and BioMarin Pharmaceutical Inc., have continued to experience slow uptake.
Key Takeaways
- With several gene therapy launches under way, manufacturers are gaining valuable commercial experience.
- Sarepta stands out as an early commercial success with Elevidys for DMD, while Vertex and bluebird are beginning to build a pipeline of sickle cell patients beginning treatment
Of the handful of companies that have launched new gene therapies during the last two years, Sarepta stands out for its early commercial win with Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?